Targeted therapies in advanced differentiated thyroid cancer.

Détails

ID Serval
serval:BIB_F34C9602386A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Targeted therapies in advanced differentiated thyroid cancer.
Périodique
Cancer treatment reviews
Auteur⸱e⸱s
Carneiro R.M., Carneiro B.A., Agulnik M., Kopp P.A., Giles F.J.
ISSN
1532-1967 (Electronic)
ISSN-L
0305-7372
Statut éditorial
Publié
Date de publication
09/2015
Peer-reviewed
Oui
Volume
41
Numéro
8
Pages
690-698
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence has been rising rapidly over the past 10 years. Although most patients with this disease have an excellent prognosis, a subset develops a more aggressive disease phenotype refractory to conventional therapies. Until recently, there was no effective therapy for these patients. With increasing knowledge of the molecular pathogenesis of thyroid cancer, novel targeted therapies are being developed for this group of patients. Sorafenib and lenvatinib, small-molecule multikinase inhibitors, were approved for the treatment of progressive, symptomatic, radioactive iodine refractory, advanced differentiated thyroid cancer in 2013 and 2015, respectively. This represents a major innovation in the therapy of patients with advanced thyroid cancer. However, these therapies still have many limitations and further research needs to be pursued with the ultimate goal of providing safe and effective personalized therapy for patients with advanced thyroid cancer.
Mots-clé
Antineoplastic Agents/pharmacology, Humans, Molecular Targeted Therapy/methods, Molecular Targeted Therapy/trends, Neoplasm Staging, Niacinamide/analogs & derivatives, Niacinamide/pharmacology, Outcome Assessment, Health Care, Phenylurea Compounds/pharmacology, Quinolines/pharmacology, Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors, Sorafenib, Thyroid Neoplasms/drug therapy, Thyroid Neoplasms/metabolism, Thyroid Neoplasms/pathology, raf Kinases/antagonists & inhibitors, Differentiated thyroid cancer, Follicular thyroid carcinoma, Targeted therapy, Thyroid cancer, Tyrosine kinase inhibitors
Pubmed
Web of science
Création de la notice
27/12/2020 14:02
Dernière modification de la notice
28/12/2020 6:26
Données d'usage